Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis

It is unclear whether aspirin is beneficial for prevention of CVD in patients with CKD. We performed a secondary analysis of the ALLHAT trial to assess the effect of baseline aspirin use on nonfatal myocardial infarction (MI) or fatal coronary heart disease (CHD), all‐cause mortality, and stroke. Ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Niraj, Wilson, Brigid, Bond, Michael, Conant, Alexander, Rahman, Mahboob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Aspirin
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029762/
https://www.ncbi.nlm.nih.gov/pubmed/33340443
http://dx.doi.org/10.1111/jch.14091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029762/
https://www.ncbi.nlm.nih.gov/pubmed/33340443
http://dx.doi.org/10.1111/jch.14091

Ejemplares similares